Standout Papers

Once-Weekly Semaglutide in Adolescents with Obesity 2022 2026 2023 2024294
  1. Once-Weekly Semaglutide in Adolescents with Obesity (2022)
    Daniel Weghuber, Timothy Barrett et al. New England Journal of Medicine

Immediate Impact

55 standout
Sub-graph 1 of 21

Citing Papers

Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss Among Adults Without Diabetes
2025 Standout
Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity
2025 Standout
2 intermediate papers

Works of Rasmus Sørrig being referenced

Effects of Semaglutide on Albuminuria and Kidney Function in People With Overweight or Obesity With or Without Type 2 Diabetes: Exploratory Analysis From the STEP 1, 2, and 3 Trials
2023
Semaglutide (SUSTAIN and PIONEER) reduces cardiovascular events in type 2 diabetes across varying cardiovascular risk
2020

Author Peers

Author Last Decade Papers Cites
Rasmus Sørrig 260 367 74 191 18 711
Daniel Lorber 125 395 47 51 24 765
Roger Rakotovao 119 296 18 75 16 726
W.-P. Koh 77 112 107 87 13 585
A. Michael Spiekerman 145 128 62 54 22 686
H. James Nickerson 154 123 51 23 19 740
Emily K. Anderson‐Baucum 248 114 23 41 22 802
D. M. Burley 120 134 55 40 16 627
Kamaljit Chatha 153 155 49 33 21 778
Eun Shil Hong 170 199 59 32 22 746
Manuel Macı́a 100 208 18 45 29 738

All Works

Loading papers...

Rankless by CCL
2026